The Journal of Pathology

Analyses of human breast carcinomas (BCs) and premalignant breast lesions show that the loss of RASSF1A is an early event in the development of ER+ BCs, which correlates linearly with malignant progression. This observation suggests that RASSF1A inhibition is important for the development and progression of ER+ BCs. In addition to RASSF1A, concurrent caveolin-1 (Cav-1) inhibition may further promote ER+ breast carcinogenesis. In the present study, transgenic Rassf1a-/- and Cav-1(-/-) single as well as Rassf1a-/-, Cav-1(-/-) double knockout mice were used to investigate the impact of single or combined Rassf1a and Cav-1 inactivation on BC initiation. Loss of either one or both proteins led to different, pre-malignant histopathological alterations within the mammary glands of the mice, but not to fully developed BC, confirming that Rassf1a and Cav-1 are both important for maintaining the integrity of mammary gland epithelial structure, but suggesting that further intracellular changes or extracellular factors are required for the development of luminal BC when both genes are lost.

Purpose: To assess the feasibility of quantitative fundus autofluorescence (FAF) measurement in early age-related macular degeneration (AMD) using the freely available ImageJ software, to characterize signal intensity across FAF patterns, and to evaluate interobserver reproducibility in pattern classification. Methods: Single-center, non-blinded, retrospective, consecutive-case analytical study. FAF images acquired with Spectralis OCT+HRA (Heidelberg Engineering) from patients with early dry AMD seen at a tertiary referral center between January 2010 and September 2016 were analyzed. A standardized 300x300-pixel region of interest (ROI) centered on the fovea was evaluated in ImageJ v2.0.0-rc54/1.51h (Fiji distribution). Mean, minimum, and maximum autofluorescence (AF) pixel intensity were recorded. Each image was independently classified according to the Bindewald classification system by two graders; a third senior grader adjudicated discordances. Cohen's kappa (k) was used to assess interobserver agreement. Results: Of 423 patients with available FAF studies, 107 had dry AMD; 45 met quality and diagnostic criteria for early AMD and were included in the quantitative analysis. Mean age was 73.47 +/- 8.1 years; 62.2% were female. Mean FAF intensity was 120.26 (range 74.76-160.79); mean minimum was 32.07 (range 3-63) and mean maximum was 205.80 (range 125-255). Seven of eight Bindewald patterns were identified; the stippled pattern was absent. The most frequent pattern was minimal changes (31.1%), followed by increased focal (24.4%) and patchy (15.6%). Reticular pattern showed the highest mean AF (143.8), while lace pattern showed the lowest (88.4). Interobserver agreement for Bindewald pattern classification was almost perfect (k = 0.969; 95% CI, 0.908-1.000; p < 0.001). Agreement for lesion extent was moderate (k = 0.531) and for foveal involvement was substantial (k = 0.622). Conclusions: Quantitative FAF evaluation of early AMD using ImageJ is feasible and reproducible. ImageJ represents a cost-free alternative for multimodal retinal image analysis, with potential for automated screening applications in resource-limited settings. Keywords: age-related macular degeneration; fundus autofluorescence; ImageJ; quantitative autofluorescence; image analysis; Bindewald classification; interobserver agreement

Background: Early detection of pancreatic ductal adenocarcinoma (PDAC) is critical. While faecal elastase-1 (FE-1) is a standard clinical marker for pancreatic function, its diagnostic accuracy for malignancy is limited. We sought to identify plasma metabolites that enhance FE-1 performance in symptomatic "at-risk" patients. Methods: Using the DEPEND cohort (CRUK C45617/A29908), plasma metabolomics was performed on patients with resectable PDAC (n=23) and healthy volunteers (n=24). Predictive modelling included feature selection and cross-validation, with further validation in an independent external cohort. Results: Citrulline was identified as significantly depleted in PDAC patients across discovery and validation cohorts. In isolation, Citrulline achieved an AUC of 0.86 (internal) and 0.88 (external validation). Standalone FE-1 demonstrated an AUC of 0.67. However, combining Citrulline and FE-1 significantly improved diagnostic performance, achieving a combined AUC of 0.96. Stratification revealed distinct metabolomic signatures associated with poorly differentiated tumours, suggesting a link to histological grade. Conclusions: Integrating Citrulline with FE-1 testing substantially improves PDAC detection in symptomatic patients. This non-invasive panel offers high diagnostic potential, though prospective validation is required to establish clinical cut-offs for routine practice.

Premature ovarian insufficiency (POI) significantly impacts quality of life, yet the immediate cognitive landscape and lived experience of younger women remain under-researched. In 125 young women (aged 19-48; 66 with idiopathic POI, 59 age-matched controls), we examined self-reported cognitive distress and symptom burden within the POI cohort and compared objective global and domain-specific cognitive performance between groups. Objective accuracy scores were derived from six online tasks (Cognitron) and combined into a robust global measure. Within the POI cohort, there were significant differences in symptom burden domains ({chi}(3) = 61.90, p<0.001), with psychological and sexual symptoms reported at a significantly higher intensity than physical and vasomotor symptoms (all p<0.001). Furthermore, the standardised magnitude of perceived cognitive distress (56.20%) was significantly greater than that of overall symptom burden (42.00%, p<0.001). Case-control comparisons revealed no significant differences in global cognitive performance (p=0.615), yet the POI cohort performed significantly less accurate than controls in verbal analogical reasoning (-0.86 SD, 95% CI: -1.52, -0.20, p = 0.011). The findings highlight an urgent need for comprehensive emotional and psychosexual support in POI care. Additionally, the presence of high cognitive distress alongside localised objective deficits demonstrates that cognitive health monitoring must be proactive in early adulthood, especially given their established long-term risks for later-life cognitive decline and dementia.

Background: Changes in the extracellular matrix (ECM) are a recognised feature of aggressive prostate cancer, but they are not exploited in clinical decision-making. We aimed to develop automated quantitative ECM parameters to facilitate risk stratification for localised prostate cancer. Methods: 378 quantitative ECM parameters were derived from picrosirius red-stained diagnostic prostate biopsies in a cohort of 422 patients, matched 1:1 for recurrence, recruited to the CHHiP (Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer) trial of radiotherapy fractionation for localised prostate cancer. These ECM parameters comprehensively described fibre architecture, gaps and ECM texture. Machine learning models at the level of both individual image tiles and patients defined how ECM parameters related to tumour versus normal prostate, Gleason grade group and recurrence. Shapley analysis was used to interpret ECM feature importance and develop signatures associated with recurrence. Results: Specific ECM patterns identified tumour versus normal prostate, Gleason pattern 4 versus 3 and recurrence. ECM patterns associated with recurrence were enriched in Gleason 4+3 patients, versus Gleason 3+4 patients. Shapley analysis revealed that biopsies from patients with recurrence had smaller more elongated gaps between fibres, with finer grained ECM texture and lower ECM homogeneity than less recurrent regions. Interpretation: Quantitative automated analysis of ECM architecture can inform probability of prostate cancer recurrence after radiotherapy; Features relating to ECM gap size and texture are of particular relevance.

Background The clinical significance of clonal hematopoiesis of indeterminate potential (CHIP) in melanoma remains incompletely defined, particularly with respect to CHIP genotype, clone size, and somatic mutations (e.g BRAF mutations). We integrated human cohort data and a syngeneic melanoma mouse model to evaluate whether CHIP is associated with melanoma risk, tumor growth, and differential clinical outcomes. Methods We analyzed CHIP prevalence and survival in a large treatment-unselected melanoma cohort (n=2,480), evaluated tumor growth in a syngeneic BRAF-mutant (BRAFmut) melanoma murine model of TET2-CHIP and DNMT3A-CHIP, and assessed survival outcomes in an immune checkpoint inhibitor (ICI)-treated advanced melanoma cohort (n=361). Associations with progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier analyses and multivariable Cox proportional hazards models. Results CHIP was enriched among patients with treatment-unselected melanoma compared with age/sex-matched healthy controls, and larger CHIP clone size showed an age-adjusted association with inferior OS. In a syngeneic BRAFmut melanoma murine model, TET2-CHIP, but not DNMT3A-CHIP, was associated with significantly increased primary melanoma tumor growth. Among patients with ICI-treated advanced melanoma, CHIP was associated with worse OS compared with patients without CHIP. TET2-CHIP had the strongest adverse association with survival, whereas DNMT3A-CHIP was not significantly associated with PFS or OS. Conclusions CHIP is enriched in melanoma and exploratory analyses demonstrate genotype-specific differences in melanoma tumor growth and clinical outcomes. These findings support further investigation of genotype-specific CHIP profiling as a potential biomarker for melanoma risk stratification and immunotherapy outcomes.

Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by death of upper and lower motor neurons, usually presented with clinical heterogeneity. Fluid biomarker development remains dominated by neurofilament light chain (NEFL), a marker of neuroaxonal injury. NEFL is however unspecific to ALS and its phenotypes and there is currently a lack of biomarkers that capture ALS heterogeneity such as onset site and ALS-frontotemporal spectrum disorder (ALS-FTSD). Therefore, we investigated whether plasma proteomics could reveal pathway-level signatures that stratify and explain ALS heterogeneity. Methods: We profiled ~5,400 plasma proteins (Olink Explore HT) in 299 patients with ALS and 50 age- and sex comparable healthy controls. We used two complementary analytic frameworks: (i) differential protein abundance analysis to identify altered proteins in ALS and across clinical subgroups, and (ii) weighted gene correlation network analysis (WGCNA) to identify coordinated protein modules and relate them to ALS diagnosis and to ALS-specific clinical traits (site of onset, ALS-FTSD, ALS functional rating scale-revised (ALSFRS-R) score, and plasma NEFL). Results: Differential abundance analysis identified 56 proteins altered in ALS versus controls, of which 40 were increased. WGCNA identified 11 co-expression modules, with ALS samples having the strongest correlation to a protein module (n=51) highly enriched for muscle-related proteins. Out of the 40 proteins that had increased expression levels, 29 overlapped with the muscle-enriched protein module, indicating that muscle related proteins are the dominant circulating proteomic signature in ALS. This signal extended to clinical stratification: spinal-onset patients showed a strong positive association with the muscle-module. Further, differential abundance analysis of spinal- versus bulbar-onset ALS identified changes that mapped predominantly to the same module, supporting a molecular signature of onset phenotype. In contrast, cognitive status (ALS-FTSD) mapped to distinct modules enriched for extracellular matrix/cell-adhesion pathways, consistent with a separable biological axis of disease heterogeneity. Although multiple modules correlated with NEFL, trait-specific signatures were not fully explained by neuroaxonal injury. Notably, the muscle-enriched module increased with higher NEFL and lower ALSFRS-R, supporting its interpretation as a severity-linked, muscle-involvement proxy. Conclusions: Large-scale plasma proteomics reveals that heterogeneity in ALS reflects underlying biological structures. We identified a dominant muscle-associated protein network that distinguished ALS patients from controls and correlated with disease onset phenotype and severity, alongside distinct protein networks linked to ALS-FTSD. By integrating differential protein abundance with network-based analysis, we defined pathway-level biomarker signatures that extend beyond NEFL, enabling biologically informed patient stratification and improved therapeutic monitoring.

Tumor-infiltrating lymphocytes (TILs) are widely used to assess antitumor immunity in breast cancer but may not reflect the functional competence of adaptive immune responses. We show that immune organization, reflected by tertiary lymphoid structures (TLS) and coordinated humoral and cellular immune programs, represents a distinct dimension of tumor immunity beyond lymphocyte abundance. By integrating histologic, transcriptomic, spatial, and immune receptor profiling analyses across multiple breast cancer cohorts, we show that immune organization is associated with greater immune repertoire diversity, evidence of therapy-induced clonal selection, and improved clinical outcomes, independent of immune infiltration. Transcriptomic measures of immune organization retained independent prognostic value across external cohorts, whereas measures of immune infiltration did not. Furthermore, treatment-induced increases in immune organization, but not immune infiltration, were associated with therapeutic response. These findings identify immune organization as a dynamic and clinically measurable state of adaptive antitumor immunity with implications for prognosis, treatment monitoring, and therapeutic development in breast cancer.

Breast cancer is a heterogeneous disease whose clinical management relies heavily on accurate molecular subtyping. The murine E0771 mammary carcinoma cell line is widely used in preclinical studies, yet its molecular identity remains controversial, with reports variably classifying it as luminal B or triple-negative. In this study, we performed an integrated molecular and functional characterization of two independently sourced E0771 cell line stocks to resolve this discrepancy. Both stocks were genetically authenticated and exhibited concordant phenotypes. Immunohistochemical and molecular analyses demonstrated absence of oestrogen and progesterone receptors, classifying E0771 as triple-negative. Functionally, E0771 cells showed no transcriptional response to oestrogen and displayed resistance to endocrine therapy both in vitro and in vivo. Collectively, our results establish E0771 as an oestrogen-independent, basal-like triple-negative breast cancer model, supporting its appropriate use in studies of hormone-resistant breast cancer biology.

Bipolar androgen therapy (BAT) exploits the paradoxical vulnerability of castration-resistant prostate cancer (CRPC) cells to rapid cycling between castrate and supraphysiologic androgen concentrations, but clinical BAT uses testosterone, which can also activate wild-type androgen receptor (AR) in androgen-responsive tissues, causing systemic side effects. 5{beta}-dihydrotestosterone (5{beta}-DHT) is a naturally occurring testosterone metabolite generally considered androgenically inactive because it binds wild-type AR weakly, yet its activity against clinically relevant AR mutants has not been systematically evaluated. Here, we tested whether 5{beta}-DHT and related 5{beta}-reduced testosterone metabolites activate AR signaling and growth programs in prostate cancer models that carry AR mutations. In C4-2 cells, 5{beta}-DHT and 3{beta}-etiocholanediol (3{beta}-ecdiol) increased canonical AR target genes, including KLK3 and TMPRSS2, with weaker activity than testosterone, whereas other 5{beta} metabolites showed limited activity. In androgen-responsive LNCaP and C4-2 models, 5{beta}-DHT and 3{beta}-ecdiol promoted cell growth under androgen-depleted conditions, and this effect was suppressed by enzalutamide, supporting AR dependence. RNA-seq confirmed that 5{beta}-DHT and 3{beta}-ecdiol induced androgen-response gene sets substantially overlapping with testosterone, albeit at lower transcriptional magnitude. Further, we found that 5{beta}-DHT, but not 3{beta}-ecdiol, suppresses cell proliferation of LNCaP, C4-2, and PC-3 cells stably expressing the clinically relevant AR gain-of-function mutants W742C and H875Y through activating AR-induced senescence-like features after high-dose exposure, consistent with the therapeutic logic of BAT. These findings identify 5{beta}-DHT as an overlooked mutant-AR agonist capable of BAT-like tumor suppression and propose it as a testosterone surrogate in BAT with potentially reduced systemic androgenic side effects. HighlightsO_LI5{beta}-DHT and 3{beta}-ecdiol promote AR-dependent prostate cancer cell growth C_LIO_LIBoth are weaker AR agonists than testosterone by RNA-seq and qPCR C_LIO_LISupraphysiologic 5{beta}-DHT suppresses growth via AR-mediated senescence C_LIO_LIGrowth suppression extends to AR mutants W742C and H875Y C_LIO_LI5{beta}-DHT may be a lower-androgenicity testosterone surrogate for BAT C_LI

Background: Cases requiring 13 or more tissue sections in Mohs micrographic surgery (MMS) demand extended operative time, additional resources, and often specialised closure techniques. Pre-operative identification of such cases would improve surgical scheduling, resource allocation, and patient counselling. We aimed to develop and validate a machine learning prediction tool using pre-operative clinical features to identify cases likely to require13 sections. Objectives: To develop and validate machine learning models for predicting which Mohs procedures will require 13 sections, using pre-operative clinical features, and to identify key predictive factors. Methods: We analysed 408 consecutive Mohs procedures with 16 pre-operative clinical variables. Thirty machine learning algorithms were evaluated, including ensemble methods (Stacking, Voting), gradient boosting (XGBoost, LightGBM, CatBoost), neural networks (3-7 layers), support vector machines, and traditional classifiers. Model performance was assessed using 5-fold stratified cross-validation and independent test set evaluation. Feature importance was determined using SHAP (SHapley Additive exPlanations) analysis. Results: The stacking ensemble achieved the highest cross-validation AUC of 0.891 (95% CI: 0.849-0.934) and test AUC of 0.884. Tumour area (cm2), calculated using the ellipse formula to approximate clinical tumour morphology, emerged as the strongest predictor (SHAP importance: 0.141), followed by tumour size dimensions (0.086 and 0.068), aggressive histopathology (0.046), and recurrence status (0.035). Wide neural network architectures (5-layer) outperformed deeper configurations (7-layer). The model demonstrated 70.7% high-confidence predictions with uncertainty <15%. Conclusions: Machine learning models using pre-operative clinical features can accurately predict which Mohs procedures will require 13 or more sections. The stacking ensemble approach provides robust predictions suitable for clinical decision support. External validation in multi-centre cohorts with diverse patient populations and practice patterns is warranted to assess model generalisability.

Background and Objective: Due to the heterogeneity of bladder cancer, minimally invasive molecular profiling may improve tumor characterization at the time of diagnosis. We evaluated whether integrated genomic and fragmentomic profiling of plasma and urinary circulating tumor DNA (ctDNA) detects BC-derived signals for diagnosis and disease stratification across all tumor stages. Methods: In this real-world cohort, 202 plasma and urine samples were obtained from 33 patients with non-muscle-invasive BC (NMIBC), mostly Ta tumors, and 15 patients with muscle-invasive BC (MIBC), as well as from 58 cancer-free controls. Low-coverage whole-genome sequencing was performed to assess ctDNA fragmentation, chromosomal instability and copy number variations. Matched tumor tissue was analyzed to evaluate concordance between liquid biopsy and tissue-derived molecular alterations. Key Findings and Limitations: Complementary genomic and fragmentomic profiling of cfDNA achieved detection rates of 75.8% in NMIBC patients and 91.7% in MIBC patients with paired plasma and urine. Distinct differences were observed between MIBC, NMIBC and cancer-free controls, consistent with increasing ctDNA signals during disease progression. Tumor tissue analysis confirmed BC-associated molecular alterations. Limitations include the single-center design and limited sample size. Conclusions and Clinical Implications: Multimodal profiling of plasma and urinary cfDNA enabled the detection of tumor-derived molecular signals for all bladder cancer stages, including early-stage disease. By integrating genomic and fragmentomic features, this minimally invasive approach provides molecular tumor characterization at the time of diagnosis and may support future risk-adapted diagnostic, therapeutic and surveillance strategies.

Importance: Neuroinflammation is a key component of the response to injury after concussion, but direct links between diffusion MRI metrics and specific plasma inflammatory pathways in human concussion have not been established. Objective: To examine associations between diffusion MRI metrics and pathway-level inflammatory proteomic signatures in adolescents during the subacute period after concussion. Design, Setting, and Participants: Cross-sectional analysis of data from the CARE4Kids Consortium, a six-site prospective study. Participants were English-speaking adolescents ages 11-17.99 with concussion and symptoms at 7-35 days post-injury. Data were collected between 2022-2024. Of 370 enrolled participants, 122 had both diffusion MRI and plasma proteomics available for analysis. Exposure: Advanced diffusion MRI metrics were converted to z-scores and participants were grouped by the spatial extent of outlier values (potholes and peaks) across 15 white matter regions of interest. Nine non-redundant groupings were selected for primary analysis. Main Outcomes and Measures: Pathway-level inflammatory profiles derived from gene set enrichment analysis (GSEA) of ~5,400 plasma proteins measured by Olink proximity extension assay, targeting nine hallmark inflammatory pathways spanning initiation through resolution. Persistent symptoms were assessed 64-115 days post-injury. Results: Diffusion metrics reflecting tissue disorganization were associated with upregulation of the coagulation pathway, consistent with hemostatic-inflammatory signaling. Metrics reflecting reduced tissue complexity and neurite density were associated with upregulation of interferon- and interferon-{gamma} response pathways, consistent with microstructural remodeling driven by cellular immune activation. Elevated free water content was associated with downregulation of most inflammatory pathways and trend-level transforming growth factor - {beta} upregulation, reflecting inflammatory resolution. Time since injury did not differ between groups based on free water (Kolmogorov-Smirnov p = 0.97), suggesting these differences reflect individual variability in recovery pace. Exploratory analyses showed a trend toward lower odds of persistent symptoms in the group with elevated free water content (odds ratio = 0.51, p = 0.18). Conclusions and Relevance: Multiple diffusion MRI metrics are differentially sensitive to distinct neuroinflammatory states in the subacute period after adolescent concussion. These findings suggest that diffusion imaging could serve as a non-invasive tool for inflammatory phenotyping, with potential implications for identifying patients who may benefit from targeted immunomodulatory intervention.

Cutaneous squamous cell carcinoma (cSCC) is the second most common form of cancer worldwide. While most cSCCs are not life-threatening, 2-5% of patients develop metastases. To better understand what causes some cSCCs to progress to metastatic disease, we assembled a nationwide cohort of 19,120 patients with clinico-pathologically annotated tumors linked to metastatic outcome. RNA-sequencing was performed on 378 tumors, and whole-exome sequencing on 147, with balanced numbers of tumors that progressed to metastatic disease (cases) and did not (controls). UV radiation was the dominant mutational signature with additional contributions from aging, APOBEC activity, and, in immunosuppressed patients, azathioprine exposure. We identified 38 genes under selection across a core set of signaling pathways. Gene expression clusters were primarily associated with the differentiation state of tumor cells and secondarily with the composition of the tumor microenvironment. Several mutational and transcriptional programs were associated with metastasis, including a dedifferentiated gene expression signature, activating mutations in the RAS signaling pathway, loss-of-function alterations in the SWI/SNF chromatin remodeling complex, and specific arm-level copy number alterations. A 23-gene expression signature was built to predict metastasis from primary cSCC tissue. The signature was validated in two independent cohorts (N=102 and 52), where it predicted metastasis independently of staging systems. Together, these findings provide the most detailed molecular portrait of cSCC to date and establish an assay for risk stratification suitable for clinical implementation.

Background: Early-onset colorectal cancer (EOCRC) is increasing globally, particularly among Hispanic/Latino (H/L) populations, yet the contribution of tumor-colonizing microbiota to age-associated colorectal cancer (CRC) biology remains poorly understood. Most microbiome studies have focused on fecal communities or non-Hispanic populations, leaving the intratumoral microbial landscape of H/L patients largely unexplored. Methods: We performed an exploratory characterization of tumor-colonizing microbiota using whole-exome sequencing (WES) data from four primary colorectal tumors obtained from H/L patients treated at City of Hope, including two EOCRC (<50 years) and two late-onset colorectal cancer (LOCRC; [&ge;]50 years) cases. Following removal of host-derived sequences, microbial taxonomic profiling was conducted at the family, genus, and species levels, and microbial metabolic pathways were inferred. Clinical and pathological data were integrated to evaluate age-associated differences in microbial composition and predicted function. Results: Family-, genus-, and species-level analyses consistently demonstrated greater microbial diversity in LOCRC than EOCRC. LOCRC contained more than twice the number of unique bacterial families, nearly three times as many unique genera, and more than twice as many unique bacterial species. A conserved core microbiota, including Fusobacteriaceae, Prevotellaceae, Fusobacterium, and Prevotella, was identified across both age groups, whereas LOCRC was enriched in CRC-associated taxa including Fusobacterium nucleatum, Bacteroides fragilis, Parvimonas micra, Porphyromonas asaccharolytica, and Dialister pneumosintes. Species-level analyses revealed only a single shared bacterial species between EOCRC and LOCRC, indicating progressive microbial divergence with increasing taxonomic resolution. In contrast, functional profiling identified 11 predicted microbial metabolic pathways, of which nine were shared between age groups, two were unique to EOCRC, and none were exclusive to LOCRC. Core metabolic pathways involved in energy metabolism, amino acid biosynthesis, phospholipid metabolism, and central carbon metabolism exhibited comparable abundance across both groups, demonstrating substantial functional conservation despite pronounced taxonomic differences. Conclusions: Tumor-colonizing microbiota differ markedly between EOCRC and LOCRC in H/L patients, with late-onset tumors exhibiting substantially greater microbial richness and taxonomic complexity. Despite these compositional differences, microbial metabolic functions remain largely conserved, supporting the concept of functional redundancy within the colorectal tumor microenvironment (TME). Although exploratory, this proof-of-concept study provides one of the first characterizations of intratumoral microbiota in H/L EOCRC and establishes a foundation for larger multi-omics investigations aimed at identifying microbiome-based biomarkers and therapeutic targets for precision oncology.

Abstract Background. Quantitative optical coherence tomography (OCT) measurements are essential for retinal disease monitoring, yet leading vendors store acquisition data in undocumented proprietary formats or encode measurements exclusively in private DICOM tags inaccessible to open systems. Methods. We present Transducin, an open-source Python library that reverse-engineers the undocumented Optopol Revo FC130 and Revo 60 .OPT binary format and extracts quantitative measurements from Zeiss Cirrus HDOCT private DICOM tags, generating TID 1500 Structured Reports with SNOMEDCT coded findings for both platforms. A novel finding, that OCTPARAMS tag 23 encodes ocular laterality through the arithmetic sign of the foveal horizontal position, enables geometry based laterality inference requiring no operator data entry, validated across 18 files from two device models and four software versions with 100% accuracy. Results. The primary corpus of 452 Optopol .OPT files (73 patients, 7 acquisition types) was parsed with 100% success. Cross-version compatibility was confirmed across SOCT versions 11.5.0 through 21.5.0, spanning approximately eight years of software development. The Zeiss Cirrus pipeline generated TID 1500 SRs for all 41 applicable studies (100%), yielding CMT 203to 630um and RNFL 53 to123 um across a clinically representative range. Conclusions. Transducin provides the first publicly documented specification of the Optopol .OPT format and the first open-source multivendor pipeline generating SNOMEDCT coded DICOM Structured Reports from both Optopol Revo and Zeiss Cirrus devices, closing a gap explicitly confirmed by both manufacturers' own documentation. The code is available at https://github.com/oftalmos-org/transducin (Apache License 2.0).

Despite continuous progress in diagnosis and therapy, breast carcinoma (BC) remains a major health problem. Triple-negative (Estrogen Receptor-/Progesterone Receptor-/HER2-) breast cancer (TNBC) is the most aggressive subtype due to its high metastatic potential and resistance to chemotherapy. The Y-box binding protein 1 (YB-1) transcription factor, a protein present in both cytoplasm and nucleus, is a driver of TNBC malignancy as it stimulates its cancer stem cell phenotype and disrupts cell cycle progression. Here, we hypothesized that YB-1-containing sEVs deliver YB-1 to the nuclear compartment of recipient cancer cells and play a major role in the activation of the metastatic process. We found a selective enrichment of YB-1 in sEVs from MDA and 4T1 cells, with [~]65% and 50% of all sEVs positive for YB-1 by d-STORM. Administration of sEVs from wild-type MDA and 4T1 to their YB-1 knockout counterparts resulted in nuclear translocation of sEV-associated YB-1 and increased tumorsphere formation. Pharmacological blockade of the nuclear transport machinery based on the inhibition of the formation of the "VOR" complex (VAP-A-ORP3-Rab7) by PRR851 impaired both nuclear translocation and the YB-1-induced increase in tumorsphere formation. YB-1 phosphorylation at S102 was required for nuclear localization. In fact, loss of YB-1 phosphorylation inhibited tumorsphere growth and stemness of cancer cells and YB-1-positive sEVs restored the oncogenic behavior of cancer cells expressing phospho-mutant YB-1. Moreover, PRR851 inhibited the nuclear translocation of the phosphorylated form of YB-1 and the oncogenic behavior of the TNBC cells. These data support the conclusion that the nuclear translocation of sEV-associated phosphorylated YB-1 is an important factor in the malignant behavior of TNBC and a potential therapeutic target.

Background Menstrual cycle disturbances have been increasingly reported after COVID-19 vaccination, raising questions about their prevalence and clinical significance among women of reproductive age. Objective This study aimed to investigate the incidence and types of menstrual cycle alterations following different doses of COVID-19 vaccines among Iranian women of reproductive age. Methods A cross-sectional survey was conducted among vaccinated women who reported their menstrual cycle status before and after each vaccine dose. Data on cycle regularity, flow characteristics, and specific menstrual disorders were collected and analyzed. Results Menstrual cycle alterations were reported by 28.8%, 25.4%, 30.3%, and 68.4% of participants after the first, second, third, and fourth vaccine doses, respectively. The most common changes were oligomenorrhea after the first and second doses (8.9% and 5.6%), menorrhagia after the third dose (5.3%), and hypomenorrhea after the fourth dose (8.3%). Comparisons with international studies revealed a wide variation in prevalence (ranging from 25% to 78%), which may be explained by differences in methodology, population characteristics, vaccine types, and pre-vaccination health status. Conclusion A considerable proportion of Iranian women experienced menstrual alterations following COVID-19 vaccination, most commonly oligomenorrhea, menorrhagia, and hypomenorrhea. While generally self-limiting, these findings highlight the need to integrate menstrual health into post-vaccination monitoring and patient counseling. Future research should explore the underlying immune-endocrine mechanisms and long-term clinical implications of these changes.

People differ widely in their sensitivity to pain, and this variability is clinically relevant, yet the underlying structural brain mechanisms remain poorly understood. White matter hyperintensities (WMH), a common imaging marker of cerebral small vessel disease, are associated with microstructural abnormalities in white matter tracts and have also been linked to pain related outcomes; however, the mechanisms linking WMH to altered pain perception remain unclear. We investigated whether WMH are linked to pain sensitivity through tract specific microstructural alterations and cortical structural differences. We analysed data from 1,448 participants (mean age 73 years; 53% women) in the population based Rotterdam Study and independently replicated the findings in 1,522 participants (mean age 63 years; 52% women) from the population based Tromso Study. Pain sensitivity was quantified using the cold pressor test. Multimodal magnetic resonance imaging, including T1 weighted, fluid attenuated inversion recovery and diffusion tensor imaging, was used to map WMH to predefined white matter tracts, derive tract specific fractional anisotropy (FA), and estimate cortical measurements. Cox proportional hazards models assessed associations with pain sensitivity, and tract specific mediation analyses evaluated whether white matter microstructure or tract connected cortical regions mediated the relationship between white matter hyperintensities and pain sensitivity. WMH were present in 20 of 27 predefined tracts and were associated with reduced FA in 18 tracts. Higher WMH burden was associated with greater pain sensitivity, particularly in the left anterior thalamic radiation and left superior thalamic radiation, while lower FA in the anterior thalamic radiation, medial lemniscus, superior thalamic radiation and inferior fronto occipital fasciculus was associated with greater pain sensitivity. Mediation analyses showed that white matter microstructural disruption was the principal pathway linking WMH to pain sensitivity, with the strongest indirect effects observed through the inferior fronto occipital fasciculus (44.6% mediated) and anterior thalamic radiation (32.6% mediated). Cortical atrophy in the precentral and postcentral gyri provided a smaller secondary pathway, mediating approximately from 3 to 6% of the association between corticospinal or superior thalamic radiation WMH and pain sensitivity. Replication analyses supported these cortical mediation pathways, and meta analysis strengthened the tract specific associations. Together, the results suggest that vascular white matter injury is associated with pain perception through specific structural pathways, with DTI based markers appearing particularly sensitive to these relationships.

Objective To evaluate adherence to published American Society for Reproductive Medicine (ASRM) infertility evaluation and treatment recommendations among commercially insured infertility patients who subsequently underwent in vitro fertilization (IVF) and to assess whether observed care gaps support the need for a restorative reproductive medical framework. Methods A retrospective claims-based analysis was performed using MarketScan(R) Commercial Claims and Encounter Data between January 1, 2021, and December 31, 2024. Approximately five million commercially insured members were evaluated. Patients with infertility-related diagnoses who subsequently underwent IVF were identified. Claims were analyzed for evidence of diagnostic testing, medical treatment, or surgical intervention recommended by ASRM or AUA/ASRM guidance before IVF initiation. Cumulative adherence rates were assessed over nine months following initial infertility diagnosis. Results IVF initiation rose early and consistently exceeded completion of nearly all guideline-recommended evaluations and treatments. Observed care gaps ranged from approximately 13% to 78% for most recommended evaluations and treatments, with several measures demonstrating gaps exceeding 50 percentage points, suggesting substantial divergence between guideline recommendations and observed clinical practice. By 3 months, IVF initiation ranged from 28% to 39% across cohorts, while adherence to many recommended interventions remained low. Overall, by 9 months, IVF utilization commonly exceeded 70-85%, while many guideline-supported evaluations and treatments remained below 40% adherence, with several interventions remaining below 15%. These findings suggest substantial divergence between published infertility-care recommendations and observed pre-IVF practice patterns. From an RRM perspective, the gaps are clinically important because many recommended steps are directed toward identifying, correcting, restoring, or preserving reproductive function and anatomy before reproductive barriers are bypassed through IVF. Conclusions Many commercially insured infertility patients appeared to progress to IVF without documented evidence of diagnostic evaluation or therapeutic intervention recommended in ASRM and AUA/ASRM guidance. These findings raise important questions regarding the implementation of infertility guidelines before IVF and the extent to which patients receive meaningful opportunities for diagnosis-directed treatment of potentially reversible causes of infertility. The findings further suggest an important role for restorative reproductive medicine as a quality-of-care framework focused on comprehensive evaluation, correction of underlying dysfunction, preservation of reproductive anatomy and physiology, and optimization of patient-centered fertility care prior to attempts with assisted reproduction.